Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2011 Financial Results
Date:8/8/2011

alization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the Food and Drug Administration (FDA). Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.

Cautionary StatementSome of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The factors that could cause our actual results to differ materially are identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the da
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results
2. Keryx Biopharmaceuticals, Inc. Prices Common Stock Offering
3. Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical
4. Keryx Biopharmaceuticals Announces Two Poster Presentations on KRX-0401 (Perifosine) at Upcoming American Association for Cancer Research (AACR) Annual Meeting
5. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year End 2010 Financial Results on Wednesday, March 9, 2011 at 8:30 a.m. ET
7. Keryx Biopharmaceuticals Announces Oral Presentation of Final Zerenex™ Short-Term Phase 3 Data at the Upcoming National Kidney Foundations 2011 Spring Clinical Meetings
8. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
9. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2010 Financial Results
10. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
11. Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... has witnessed robust development with the growth pace keeping at ... In 2012, the size of China ... worldwide soaring to 16.3%. It is projected that ... rate by around 20% in the upcoming years and that ... An integrated membrane industrial system has taken shape ...
(Date:12/17/2014)... -- Los beneficios y ganancias están por ... gasto en investigación y desarrollo   En ... septiembre de 2014) ZEISS aumentó sus ingresos en un ... anterior: 4.190 millones de euros) a pesar de los ... un 14 por ciento, a 360 millones de euros. ...
(Date:12/17/2014)...  Strategic Health Services, Inc. (SHS), a leading provider ... strategic agreement with QualCare, Inc., a leading provider of health ... regional marketplace.  This agreement will further QualCare,s population health ... QualCare brings to its clients in New ... QualCare plans cover more than 800,000 member lives, ...
Breaking Medicine Technology:Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3ZEISS confirma su posición en un entorno difícil 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 3
... May 24, 2007 - Cytos,Biotechnology AG (SWX:CYTN) ... phase I/IIa study with,CYT007-TNFQb, a novel vaccine ... inflammatory conditions. The present study was,a first-time-in-man ... moderate to severe plaque psoriasis. In a ...
... 1 Studies with Monoclonal Antibody,Targeting Interleukin-9 (IL-9); ... in Developing Potential Asthma,Therapies, GAITHERSBURG, Md., May ... the presentation of data,highlighting recent progress within ... two Phase 1 clinical,studies with its monoclonal ...
Cached Medicine Technology:Cytos Reports Results from Phase I/IIa Study with CYT007-TNFQb for,the Treatment of Psoriasis 2Cytos Reports Results from Phase I/IIa Study with CYT007-TNFQb for,the Treatment of Psoriasis 3Cytos Reports Results from Phase I/IIa Study with CYT007-TNFQb for,the Treatment of Psoriasis 4MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 2MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 3MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 4MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 5MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 6MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 7
(Date:12/19/2014)... December 19, 2014 B. E. Smith, ... healthcare providers, has been retained to lead a national ... Medical Center in Estes Park, Colo. The top executive ... has recently placed more than 900 healthcare executives into ... a 25-bed, not-for-profit critical access hospital and level IV ...
(Date:12/19/2014)... December 19, 2014 The global ... capital equipment market that is saturated with numerous ... and efficacy as well as non-invasive nature, MRI ... first introduced to the healthcare market. Rapid advances ... of MRI safe technologies have greatly expanded the ...
(Date:12/19/2014)... On Mobile Spa, has announced they now have a ... transformed into a utopia for the Long Island community where ... Virtual Tour showcases the beauty of the Spa On Wheels ... , The Virtual Tour shows viewers each of the rooms ... Winnebago. Marla Kaplan-Pelle, Director states " It's hard to imagine ...
(Date:12/19/2014)... FL (PRWEB) December 19, 2014 If ... someone having difficulty breathing, you probably wished you had ... of asthma, COPD, cystic fibrosis, and other breathing disorders. ... prescription medications and avoiding triggers, but other common treatments ... Asthma Educators conference in San Antonio, TX, 34 asthma ...
(Date:12/19/2014)... Slone Partners , a national recruitment ... technology, and laboratory testing industries, has promoted Leslie ... The announcement comes after a year of expansion ... in Boston and several new additions to the ... client experience," said Adam Slone, Chief Executive Officer. ...
Breaking Medicine News(10 mins):Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 3Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 2Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 3Health News:Magnetic Resonance Imaging Systems Market Analysis and Forecast to 2020 Report at RnRMarketReserach.com 4Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 2Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 3Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 2Health News:Harmonica Techs, Inventors of the Pulmonica®, Unveil New Findings on Complementary Treatments for Asthma 3Health News:Slone Partners Promotes Leslie Loveless to Chief Operating Officer 2
... 21 (HealthDay News) -- Obese patients are more likely than ... cancer when they,re diagnosed with the disease, a new study ... the United States and most of that increase is due ... at the University of California-Los Angeles David Geffen School of ...
... MONDAY, May 21 (HealthDay News) -- Women who exercise vigorously ... report. Psoriasis is an immune disorder that causes inflammation ... for up to three hours a week can potentially reduce ... said. "Exercise is a modifiable risk factor. Here is ...
... 2012. West Orange, NJ. Scientists at Kessler Foundation ... multiple sclerosis at the Hilton San Diego Bayfront in ... Nancy Chiaravalloti and Yael Goverover are addressing the ... Centers (CMSC) and the Americas Committee for Treatment and ...
... 21, 2012) Behavioral support from peers and primary care ... by as much as starting a new drug, a new ... UT Medicine San Antonio, is the senior author. The ... behavioral support from peers and primary care office staff ...
... -- Heart damage can be present in obese teens who don,t ... Obesity is a risk factor for heart disease, and previous ... In the new study, researchers examined the heart structure and ... obese -- with no symptoms of heart disease. The results ...
... General Hospital (MGH) surgeons have developed a new technique ... In the May Annals of Otology, Rhinology ... which uses cryopreserved aortas from deceased donors to replace ... permanent tracheotomy and maintain voice and swallowing function with ...
Cached Medicine News:Health News:Obese More Likely to Be Diagnosed With Advanced Thyroid Cancer 2Health News:Vigorous Exercise Might Keep Psoriasis at Bay 2Health News:Vigorous Exercise Might Keep Psoriasis at Bay 3Health News:Kessler Foundation scientists present cognitive research findings at MS dual symposium 2Health News:Behavioral support from peers, staff lowers patients' blood pressure 2Health News:Behavioral support from peers, staff lowers patients' blood pressure 3Health News:Obese Teens Can Have Heart Damage Without Showing Signs 2Health News:Donor aortic graft improves reconstruction after partial laryngectomy 2
This 16-bit integrated and cooled system is a completely self contained unit built with a long list of standard features including all-electronic-variable transilluminator and EPI lighting....
This true 8-bit integrated and cooled imaging system is a completely self contained unit built with a long list of standard features including all-electronic-variable transilluminator and EPI lightin...
... ACS:180 SE is a major ... consisting of important physical and ... routine operation and increase efficiency. ... "Next Generation" ACS:180. The productivity ...
... of Platelet aggregometers allows to choose ... needs. Single, dual and four sample ... outputs or digital computer outputs. In ... which measure platelet aggregation in platelet-rich-plasma ...
Medicine Products: